Several mutations regarding driver genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 protooncogene receptor tyrosine kinase (ROS1), and serine/threonine protein kinase v-Raf murine sarcoma viral oncogene homolog B (CRAF) were discovered in NSCLC, which increased treatment options against NSCLC significantly [83]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.